[HTML][HTML] Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …
exceeds 35 years in young patients, but its natural history might be interrupted by …
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
JP Bewersdorf, S Giri, R Wang, N Podoltsev… - Leukemia, 2021 - nature.com
Data on the efficacy and safety of interferon (IFN)-α for the treatment of essential
thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. We conducted a …
thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. We conducted a …
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
T Barbui, AM Vannucchi, V De Stefano… - The Lancet …, 2021 - thelancet.com
Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …
[HTML][HTML] High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
T Barbui, AM Vannucchi, A Alvarez-Larran, A Iurlo… - Leukemia, 2021 - nature.com
We report the clinical presentation and risk factors for survival in 175 patients with
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and …
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and …
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
G Abu-Zeinah, S Krichevsky, T Cruz, G Hoberman… - Leukemia, 2021 - nature.com
Interferon-alpha (rIFNα) is the only disease-modifying treatment for polycythemia vera (PV),
but whether or not it prolongs survival is unknown. This large single center retrospective …
but whether or not it prolongs survival is unknown. This large single center retrospective …
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
D Luque Paz, J Riou, E Verger, B Cassinat… - Blood …, 2021 - ashpublications.org
We aimed to study the prognostic impact of the mutational landscape in primary and
secondary myelofibrosis. The study included 479 patients with myelofibrosis recruited from …
secondary myelofibrosis. The study included 479 patients with myelofibrosis recruited from …
[HTML][HTML] JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
P Guglielmelli, GG Loscocco, C Mannarelli… - Blood cancer …, 2021 - nature.com
Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …
2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management
H Ali, A Bacigalupo - American Journal of Hematology, 2021 - Wiley Online Library
The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …
[HTML][HTML] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
F Cervantes, DM Ross, A Radinoff, F Palandri… - Leukemia, 2021 - nature.com
Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for
effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) …
effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) …
[HTML][HTML] Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
A Rambaldi, A Iurlo, AM Vannucchi, B Martino… - Blood cancer …, 2021 - nature.com
Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN)
characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic …
characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic …